The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...

An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Sometimes, a delay is caused by a patent review, so the PTO will compensate a pharmaceutical company by extending the life of ...

(Alliance News) - GSK PLC on Wednesday said it reached two confidential settlements regarding the Zantac case in California State Court. The London-based pharmaceutical company said the cases ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...